FDA approves Qelbree, a Non-stimulant Treatment for ADHD
The FDA has approved Qelbree (SPN-812), for children aged 6 to 17 years with attention deficit hyperactivity disorder (ADHD)....
The FDA has approved Qelbree (SPN-812), for children aged 6 to 17 years with attention deficit hyperactivity disorder (ADHD)....
Parkinson’s disease, the most common neurodegenerative movement disorder has growing prevalence with the age. Due to increasing life expectancy...
Patients with diabetes are at risk of cardiovascular disease. Heart failure, myocardial infarction, and stroke are all more common...
Blood tests make diagnosis easier, but blood test and biomarkers for traumatic brain injury have historically been lacking. Now,...
On December 31, 2019, a cluster of cases with pneumonia of unknown cause was detected in Wuhan, China. Later...
Dementia is a syndrome affecting memory, cognition, and behavior of the affected person. It is a common symptom of...
US Food and Drug Administration (FDA) has warned both patients and doctors alike about the use of balloon angioplasty...
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder associated with both motor as well as non-motor symptoms (NMS). Though...
Fecal microbiota transfer is performed by processing donor feces, screening it for disease causing viruses and bacteria, and then...
Guillain-Barre syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system (1) and resulting in muscle weakness, and...